PURPOSE: Hypoxia may influence gene expression to promote malignancy, and acute hypoxia has been shown to transiently repress estrogen receptor (ER)-alpha expression in breast cell lines. However, the effect of intermittent hypoxia, which is likely more prevalent in breast cancers, remains to be determined. EXPERIMENTAL DESIGN: ER-alpha expression was assessed by Western blot and immunohistochemistry in a selected cohort of 51 ER-alpha-positive breast carcinomas, in relation to markers of hypoxia. The effect of acute and intermittent hypoxia on ER-alpha expression was also determined in MCF7 and ZR-75 breast cell lines, together with the role of proteasome function with the proteasome inhibitor bortezomib. RESULTS: Regional loss of ER-alpha expression occurs in breast tumors and is consistently present in hypoxic regions defined by the proximity of necrosis and induction of hypoxia-induced genes carbonic anhydrase IX (CA-IX) and glucose transporter 1 (Glut-1), in both in situ (n = 29; P < 0.0001) and invasive (n = 20; P = 0.0001) carcinomas. In MCF7 and ZR-75 cells, ER-alpha is transiently down-regulated by acute hypoxia and rapidly restored by reoxygenation. However, intermittent, acute hypoxia can cause a similar down-regulation of ER-alpha that is not attributable to decreased mRNA and persists in MCF7 cells despite reoxygenation for up to 14 days. This effect occurs with no change in cell viability but a corresponding reduction in growth response to estradiol. However, ER-alpha expression can be restored by bortezomib. CONCLUSIONS: Intermittent hypoxia can cause persistent changes in proteasome function that may contribute to reduced ER-alpha expression in breast tumors and consequently to diminished response and development of resistance to endocrine therapy.
PURPOSE:Hypoxia may influence gene expression to promote malignancy, and acute hypoxia has been shown to transiently repress estrogen receptor (ER)-alpha expression in breast cell lines. However, the effect of intermittent hypoxia, which is likely more prevalent in breast cancers, remains to be determined. EXPERIMENTAL DESIGN:ER-alpha expression was assessed by Western blot and immunohistochemistry in a selected cohort of 51 ER-alpha-positive breast carcinomas, in relation to markers of hypoxia. The effect of acute and intermittent hypoxia on ER-alpha expression was also determined in MCF7 and ZR-75 breast cell lines, together with the role of proteasome function with the proteasome inhibitor bortezomib. RESULTS: Regional loss of ER-alpha expression occurs in breast tumors and is consistently present in hypoxic regions defined by the proximity of necrosis and induction of hypoxia-induced genes carbonic anhydrase IX (CA-IX) and glucose transporter 1 (Glut-1), in both in situ (n = 29; P < 0.0001) and invasive (n = 20; P = 0.0001) carcinomas. In MCF7 and ZR-75 cells, ER-alpha is transiently down-regulated by acute hypoxia and rapidly restored by reoxygenation. However, intermittent, acute hypoxia can cause a similar down-regulation of ER-alpha that is not attributable to decreased mRNA and persists in MCF7 cells despite reoxygenation for up to 14 days. This effect occurs with no change in cell viability but a corresponding reduction in growth response to estradiol. However, ER-alpha expression can be restored by bortezomib. CONCLUSIONS: Intermittent hypoxia can cause persistent changes in proteasome function that may contribute to reduced ER-alpha expression in breast tumors and consequently to diminished response and development of resistance to endocrine therapy.
Authors: Tetiana V Serebrovska; Alla G Portnychenko; Tetiana I Drevytska; Vladimir I Portnichenko; Lei Xi; Egor Egorov; Anna V Gavalko; Svitlana Naskalova; Valentina Chizhova; Valeriy B Shatylo Journal: Exp Biol Med (Maywood) Date: 2017-07-31
Authors: William J Irvin; Robert Z Orlowski; Wing-Keung Chiu; Lisa A Carey; Frances A Collichio; Philip S Bernard; Inge J Stijleman; Charles Perou; Anastasia Ivanova; E Claire Dees Journal: Clin Breast Cancer Date: 2010-12-01 Impact factor: 3.225
Authors: J Quincy Brown; Lee G Wilke; Joseph Geradts; Stephanie A Kennedy; Gregory M Palmer; Nirmala Ramanujam Journal: Cancer Res Date: 2009-03-17 Impact factor: 12.701
Authors: Gabi U Dachs; Maiko Kano; Ekaterina Volkova; Helen R Morrin; Valerie C L Davey; Gavin C Harris; Michelle Cheale; Christopher Frampton; Margaret J Currie; J Elisabeth Wells; Bridget A Robinson Journal: BMC Cancer Date: 2010-10-10 Impact factor: 4.430
Authors: Suleiman Massarweh; Jessica Moss; Chi Wang; Edward Romond; Stacey Slone; Heidi Weiss; Rouzan G Karabakhtsian; Dana Napier; Esther P Black Journal: Future Oncol Date: 2014-12 Impact factor: 3.404
Authors: Loris De Cecco; Valeria Musella; Silvia Veneroni; Vera Cappelletti; Italia Bongarzone; Maurizio Callari; Barbara Valeri; Marco A Pierotti; Maria Grazia Daidone Journal: BMC Cancer Date: 2009-11-24 Impact factor: 4.430